Companies:

 

Articles:

 
Biotech

Neurizon Therapeutics reports positive study results on human brain model by neuroprotective candidate NUZ-001

Go to Imelda Cotton author's page
By Imelda Cotton - 
Neurizon Therapeutics ASX NUZ NUZ-001 Positive Results Human 3D Brain Model
Copied

Neurizon Therapeutics (ASX: NUZ) has reported positive results from an independent study into the effects of neuroprotective candidate NUZ-001 on a 3D human brain model developed by Tessara Therapeutics.

The results showed that NUZ-001 and NUZ-001 sulfone (the major active metabolite) exhibited strong safety characteristics in Tessara’s ArtiBrain model over a three-day period at doses ranging from 5 micrometres to 50μM.

The compounds offered protection against a newly identified form of cell death known as ferroptosis that has been implicated in conditions such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis, where lipid peroxidation is a mechanism of neurodegeneration.

Micro-tissues technology

Tessara has developed RealBrain 3D human micro-tissues technology to replicate the biological complexity of the human brain in a scalable and reproducible manner.

Neurizon is utilising the company’s ArtiBrain (healthy human brain) and ADBrain (Alzheimer’s disease) models to explore the effect of NUZ-001 as part of an ongoing collaboration.

Neurizon belives that short-term treatment with NUZ-001 and NUZ-001 sulfone can promote the health and viability of brain tissues, offer neuroprotective properties against neurotoxic insult and promote neuroplasticity by boosting neuronal branching.

Encouraging results

Tessara chief executive officer Dr Christos Papadimitriou said the latest study results were encouraging for Neurizon’s work.

“Our current data suggest that longer-term treatment may enhance network density and overall plasticity,” he said.

“In humans, this could translate into tangible benefits in cognition, learning, memory or resilience to neurodegenerative processes involved in diseases such as Alzheimer’s and Parkinson’s.”

Conference presentation

Tessara principal scientist and Alzheimer’s expert Dr Mark Greenough will present Neurizon’s study results at the AD/PD 2025 Advances in Science & Therapy conference in Austria this week.

The annual event attracts medical and scientific professionals from around the world and remains at the forefront of unravelling the mechanisms and improving the treatment of Alzheimer’s, Parkinson’s and related neurological disorders.

Neurizon expects the presentation to provide strong independent support for its ongoing development of NUZ-001.